证券记录 · 已归档季度
VRNA
Verona Pharma plc · Healthcare · Biotechnology
9被追踪持有人
—Δ持有人
3.45M持有股份
$49.92M报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2025 | 17 | -1 | 15.38M | $1.64B | +3 | −4 |
| Q2 2025 | 15 | +1 | 9.80M | $926.97M | +1 | — |
| Q1 2025 | 12 | +1 | 8.25M | $524.09M | +1 | — |
| Q4 2024 | 11 | +3 | 8.58M | $398.41M | +3 | — |
| Q3 2024 | 8 | -1 | 5.38M | $154.86M | +1 | −2 |
| Q2 2024 | 9 | — | 3.45M | $49.92M | — | — |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.57M | — | $22.72M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 1.57M | — | $22.72M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.57M | — | $22.72M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.57M | — | $22.72M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.57M | — | $22.72M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 949.38K | — | $13.73M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 527.64K | — | $7.63M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 175.00K | — | $2.53M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 102.61K | — | $1.48M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 102.61K | — | $1.48M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (被动) | 65.94K | — | $953,550 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 31.04K | — | $448,896 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 15.80K | — | $228,425 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 13.50K | — | $195,210 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据